INTRODUCTION {#sec1}
============

Adequate availability of essential PUFAs and the long-chain PUFA (LC-PUFA) metabolites of both the n--6 and n--3 (families is important in every stage of human life from pregnancy to adulthood, because these fatty acids modulate motor and cognitive function, mental health, cardiovascular function, and inflammatory responses, such as allergies and eczema ([@bib1], [@bib2]). However, studies on the effects and the magnitude of these effects remain inconclusive ([@bib3]). For example, the authors of a meta-analysis that explored the effects of LC-PUFA supply in infant formula on vision and neurodevelopment concluded that although some studies showed significant benefits, overall, no significant effect was detectable ([@bib4]). With regards to allergies, limited evidence supports a benefit of maternal n--3 LC-PUFA intake during pregnancy or lactation for reducing allergic disease in children ([@bib5]). Caution is needed when interpreting current evidence, as many of the included trials had methodologic limitations such as small sample sizes, high attribution rates, and a lack of intention-to-treat analyses ([@bib3]).

Studies published in the last decade have demonstrated a marked impact of single-nucleotide polymorphisms (SNPs) in the fatty acid desaturase (*FADS*) gene clusters on the activity of *FADS* enzymes, as well as precursor PUFA and LC-PUFA levels in blood and tissue ([@bib6]). Desaturase enzymes convert precursor PUFAs, namely linoleic acid (LA) and α-linolenic acid (ALA), through a desaturation and elongation process, to LC-PUFA metabolites such as arachidonic acid (ARA), EPA, and DHA. In European populations, minor allele carriers of *FADS* SNPs had increased substrate amounts (LA and ALA) and decreased product amounts (ARA, EPA, and DHA), which are reflective of reduced desaturase enzyme activity, as shown in numerous studies involving a wide range of subjects (69--4457), and genome-wide associations ([@bib9], [@bib16], [@bib17]).

As most previous studies have been conducted in European populations ([@bib9]), we studied variants of the *FADS1, FADS2*, and *FADS3* genes in Indonesian newborns and their relation to LC-PUFA composition in umbilical artery plasma. Our primary endpoint was to characterize the impact of genetic variation in the *FADS1--3* gene clusters on plasma LC-PUFA composition in cord blood. The secondary endpoints were the characterization of the frequency of *FADS1, FADS2*, and *FADS3* gene SNPs in the Indonesian population, their relation to the fatty acid composition of umbilical artery plasma lipids, and differences in minor alleles among various populations.

METHODS {#sec3}
=======

Study area and population {#sec3-1}
-------------------------

We performed a cross-sectional analysis among 390 mother-infant pairs from the Indonesian Prospective Study of Atopic Dermatitis in Infants (ISADI). The primary endpoint of the ISADI research was to assess the role of filaggrin (*FLG*) gene mutation, *FADS1*/*FADS2* gene polymorphisms, and LC-PUFAs in atopic dermatitis patients ([@bib18]). Our investigation of *FADS1*/*FADS2* gene polymorphisms and LC-PUFAs in all infants is complete, but genetic exploration of the *FLG* gene is not yet complete. Based on the available data, we explored the impact of *FADS* gene cluster SNPs on the LC-PUFA composition of cord blood lipids.

We used a consecutive sampling procedure to collect participants. The number of participants was calculated using the formula of categoric descriptive sample size. The study was conducted at Kemayoran Primary Health Care, central Jakarta, from April 2014 to December 2015. Participants were apparently healthy newborn infants whose parents agreed to participate in the study, and provided written informed consent.

Inclusion criteria were apparently healthy newborns born at term (37--42 wk of gestation) with a birth weight ≥2500 g, to mothers with normal gestational history and who had omnivorous diets.

Exclusion criteria were serious congenital anomalies or diseases in the infant, maternal gestational hypertension, gestational diabetes mellitus, or other severe illness, disorders, or the intake of n--3 and n--6 supplements by the mother during pregnancy and breastfeeding, or by the infant.

Ethics {#sec3-2}
------

The present study was conducted according to the International Ethical Guidelines for Biomedical Research Involving Human Subjects. All procedures were approved by the Permanent Medical Research Ethics Committee in Medicine and Health/Faculty of Medicine Universitas Indonesia/Dr Cipto Mangunkusumo Hospital (47/H2.F1/ETIK/2014, extended by letter 148/UN2.F1/ETIK/2015). Written informed consent was obtained from all parents of the study subjects. The study was registered at clinicaltrials.gov as NCT02401178.

Procedures {#sec3-3}
----------

### Sample collection and handling {#sec3-3-1}

Umbilical artery blood specimens were collected into EDTA tubes directly after birth, but before detachment of the placenta. Specimens were immediately centrifuged. The plasma and buffy coat were frozen at −80°C, transported on dry ice to LMU, Munich, Germany, and stored at −80°C until further analysis.

### LC-PUFA measurements {#sec3-3-2}

Plasma glycerophospholipid fatty acids were quantified as described previously ([@bib18]). Briefly, selective preparation of methyl ester derivatives of glycerophospholipid fatty acids was achieved by coprecipitation of triacylglycerols and cholesterol esters with proteins and base-catalyzed transesterification excluding methyl ester synthesis from nonesterified fatty acids. Aliquots (100 µL) of EDTA plasma were combined with methanol containing dipentadecanoyl phosphatidylcholine as an internal standard. Tubes were centrifuged (3030 $\documentclass[12pt]{minimal}
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}{}$\times$\end{document}$ g; 10 min; 4ºC) and the supernatant transferred to another vial. Sodium methoxide solution was added for fatty acid methyl ester (FAME) synthesis from glycerophospholipid fatty acids at room temperature. After 4 min, the reaction was stopped with methanolic HCl, and the FAME was extracted into 1 mL hexane for gas chromatographic analysis. The FAME was quantified by gas chromatography with flame ionization detection (Agilent 7890 GC; Agilent, Waldbronn, Germany), using a 50-m, 0.22-mm inner diameter BPX70 column (SGE, Weiterstadt, Germany). Injection was performed with a programmable temperature vaporizer (Gerstel, Mühlheim, Germany) to avoid preconcentration of hexane extracts before gas chromatography. FAME peaks were identified and calibrated relative to pentadecanoic acid methyl ester (internal standard) by comparison with a FAME standard mixture (GLC-569B; Nu-Check Prep, Inc., Elysian, MN). Agilent Chemstation (revision B.04.03) was used for peak integration. Interassay coefficients of variation were determined by analysis of multiple aliquots of a sample distributed within the analysis of study subjects. Fatty acid results are reported as a percentage of total fatty acids analyzed (% wt/wt) ([@bib19]). In this analysis, 12 PUFA measurements were included, namely LA (C18:2n--6), γ-linolenic acid (C18:3n--6), eicosadienoic acid (C20:2n--6), dihomo-γ-linolenic acid (DGLA/C20:3n--6), ARA (C20:4n--6), adrenic acid (C22:4n--6), docosapentaenoic acid (DPA, C22:5n--6 and C22:5n--3), ALA (C18:3n--3), eicosatrienoic acid (C20:3n--3), eicosapentaenoic acid (EPA, C20:5n--3), and docosahexaenoic acid (DHA, C22:6n--3).

### Genotyping {#sec3-3-3}

*FADS1, FADS2*, and *FADS3* SNP analysis was performed at the Research Unit of Molecular Epidemiology at Helmholtz Zentrum Munich, Germany, as previously described ([@bib20]). DNA was extracted from the buffy coat of umbilical artery blood by the Puregene DNA isolation kit (Gentra Systems). Genotyping was performed using iPLEX Gold Chemistry (Sequenom) and matrix-assisted laser desorption ionization-time of flight mass spectrometry, with methods to detect allelic differences. In brief, locations containing certain SNPs were amplified by polymerase chain reaction, using specific primers. After deactivation by alkaline phosphatase, single-base elongation was performed in accordance to the print order. After salt ion removal by ion switch and elongation reaction, the specimen was transferred to a silicone chip and covered with 3-hydroxypicolinic acid. The differences from specific alleles were measured by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Allele recognition from SNPs was performed by Mass ARRAY Typer version 4.0.5 (Sequenom). SNPs for *FADS* genes were selected based on 3 criteria: *1*) the SNP has been studied in previous publications; *2*) the SNP candidates being considered are SNPs that have already been shown to be associated with LC-PUFA status; and *3*) minor allele frequency (MAF) \>10%.

Statistical analysis {#sec3-4}
--------------------

All data processing was performed with SAS version 9.4 (SAS Institute Inc, NC), or R 3.2.4 (<http://www/r-project.org>). Allele frequency, Hardy-Weinberg equilibrium (HWE), and linkage disequilibrium were assessed with R-package Genetics (<https://cran.r-project.org/web/packages/genetics/index.html>). The linkage disequilibrium test for each pair of SNP loci was tested with Lewontin\'s D′. Normal distribution of fatty acid was assessed by the Kolmogorov-Smirnov test. Regression analysis was performed to explore the associations between the genetic variation of *FADS1* to *FADS3* genes and LC-PUFA composition ([@bib21]). Reported *P* values in tables are uncorrected for multiple testing, with \*\*\* indicating significance after Bonferroni correction to account for multiple testing (critical corrected *P* value is *P *\< 1.84 × 10^--4^, i.e., usual α of 0.05 divided by the number of tests = 17 SNPs × 16 fatty acid outcomes).

RESULTS {#sec4}
=======

A total of 390 healthy infants, 190 girls and 200 boys, who met the inclusion criteria were enrolled in this study. The mean ± SD birth weights were 3022 ± 337.2 g for girls and 3132.1 ± 399 g for boys. The mean Apgar scores were 9 at 1 min, and 10 at 5 min. The average maternal age of delivery was 27.5 y. Most parents came from low socioeconomic backgrounds with senior high school education.

No statistical differences in the fatty acids were found between boys and girls for any of the n--6 and n--3 fatty acids, except for ALA and the ratio of EPA to ALA ([**Table 1**](#tbl1){ref-type="table"}). The ratios of ARA to LA, as well as EPA and DHA to ALA, were calculated as markers of the activity of fatty acid desaturation mediated by the enzymes D5D and D6D, respectively. The ratio of DGLA to LA is used to indicate the D6D activity, whereas D5D activity is reflected by the ratio of ARA to DGLA.

###### 

Fatty acid content (wt%) of cord plasma glycerophospholipids^[1](#tb1fn1){ref-type="table-fn"}^

                 Girls          Boys                     Total
  -------------- -------------- -------------- --------- --------------
  n--6                                                   
   18:2 (LA)     8.62 ± 1.15    8.74 ± 1.17    0.297     8.68 ± 1.16
   18:3 (GLA)    0.16 ± 0.03    0.16 ± 0.04    0.678     0.16 ± 0.04
   20:2 (EDA)    0.49 ± 0.11    0.50 ± 0.13    0.262     0.49 ± 0.12
   20:3 (DGLA)   5.63 ± 0.91    5.60 ± 0.80    0.727     5.62 ± 0.85
   20:4 (ARA)    15.71 ± 1.56   15.44 ± 1.71   0.101     15.57 ± 1.65
   22:4 (DTA)    0.65 ± 0.12    0.64 ± 0.11    0.576     0.64 ± 0.12
   22:5 (DPA)    1.27 ± 0.34    1.29 ± 0.33    0.448     1.28 ± 0.33
   20:3/18:2     0.66 ± 0.12    0.65 ± 0.13    0.445     0.66 ± 0.12
   20:4/20:3     2.89 ± 0.71    2.84 ± 0.68    0.458     2.87 ± 0.69
   20:4/18:2     1.86 ± 0.35    1.81 ± 0.38    0.144     1.83 ± 0.37
  n--3                                                   
   18:3 (ALA)    0.05 ± 0.03    0.06 ± 0.02    0.023\*   0.05 ± 0.03
   20:3 (ERA)    0.13 ± 0.02    0.14 ± 0.02    0.156     0.14 ± 0.02
   20:5 (EPA)    0.12 ± 0.07    0.11 ± 0.05    0.162     0.11 ± 0.06
   22:5 (DPA)    0.24 ± 0.10    0.22 ± 0.08    0.180     0.23 ± 0.09
   22:6 (DHA)    5.17 ± 1.24    5.06 ± 1.02    0.342     5.12 ± 1.14
   20:5/18:3     2.49 ± 1.51    2.05 ± 1.08    0.001\*   2.26 ± 1.32

^1^Values of the wt% are means ± SDs. *P*value is from *t* test for the difference in measurements between girls and boys. \*Significant differences, *P* \< 0.05. Enzyme activity of D5D was determined by the ratio of ARA/DGLA. Enzyme activity of D6D was determined by the ratio of DGLA/LA. ALA, α-linolenic acid; ARA, arachidonic acid; DGLA, dihomo-γ-linolenic acid; DPA, docosapentaenoic acid; DTA, docosatetraenoic acid; EDA, eicosadienoic acid; ERA, eicosatrienoic acid; GLA, γ-linolenic acid; LA, linoleic acid.

The distribution of all 18 *FADS1, FADS2*, and *FADS3* SNPs genotyped in this study population is presented in [**Table 2**](#tbl2){ref-type="table"}. Genotyping was done along a 34-kb portion from position 618,393,876 (rs174548) to position 61,888,645 (rs174455). The positions in base pairs were defined according to genome build 108, assembly GRCH38.p2 (<https://www.ncbi.nlm.nih.gov/snp>). This lists major and minor *FADS* alleles, MAF, and *P* values of the HWE tests. One of the SNPs (rs968567) was monomorphic in the study and, therefore, could not be analyzed further. The other 17 SNPs of the ISADI study were consistent with HWE. The SNPs rs174548, rs174556, and rs174561 had an almost identical MAF of 27% and were highly collinear (the linkage disequilibrium calculation gave a D′ value of 0.99999). Consequently, 14 SNPs were included in further analyses to avoid informational repetition.

###### 

Characteristics of SNPs analyzed in the *FADS1*--*FADS3* gene clusters in Indonesian infants^[1](#tb2fn1){ref-type="table-fn"}^

  Gene         dbSNP build 108   Position, bp   Major/minor alleles    MAF, %   HWE *P* value
  ------------ ----------------- -------------- ---------------------- -------- ---------------
  *FADS*1      rs174548          61,803,876     C/G                    27       0.696
               rs174556          61,813,163     A/G                    27       0.696
               rs174561          61,815,236     G/A                    27       0.696
  Intergenic   rs3834458         61,827,449     del/T                  22       0.456
               rs968567          61,828,092     C/T                    NA       NA
  *FADS*2      rs174570          61,829,740     T/C                    23       0.477
               rs174574          61,832,870     A/C                    22       0.548
               rs2727271         61,835,886     A/T                    25       0.685
               rs174576          61,836,038     A/C                    22       0.368
               rs174578          61,838,027     A/T                    22       0.368
               rs174579          61,838,141     C/T                    28       1.000
               rs174602          61,856,942     C/T                    41       0.465
               rs498793          61,857,233     C/T                    15       0.421
               rs526126          61,857,413     C/G                    22       0.056
               rs174575          61,834,531     C/G                    30       1.000
  Intergenic   rs174448          61,872,101     T/C                    48       0.760
               rs174449          61,872,907     C/T                    47       0.186
  *FADS*3      rs174455          61,888,645     C/T                    45       0.474

^1^dbSNP, database single-nucleotide polymorphism; del., deleted; *FADS*, fatty acid desaturase; HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; NA, not available.

[**Table 3**](#tbl3){ref-type="table"} compares the MAF of the *FADS* genes among different populations in Indonesia, the Mexican POSGRAD (Prenatal Omega-3 Supplementation on Child Growth and Development) Study ([@bib22]), and Europe; data from the latter come from the HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) Study, which included 9 countries ([@bib23]), the British ALSPAC (Avon Longitudinal Study of Parents and Children) Study ([@bib20]), the German LISA (Influences of Lifestyle-related Factors on the Immune System and the Development of Allergies in Childhood) Study, and the KOALA ("Kind, Ouders en gezondheid: Aandacht voor Leefstijl en Aanleg") Birth Cohort Study in the Netherlands ([@bib8]).

###### 

Comparison of common single-nucleotide polymorphisms among different populations^[1](#tb3fn1){ref-type="table-fn"}^

  Gene         dbSNP build 108   ISADI   MAF, %   POSGRAD   MAF, %   ALSPAC   MAF, %   KOALA   MAF, %   LISA   MAF, %   HELENA   MAF, %
  ------------ ----------------- ------- -------- --------- -------- -------- -------- ------- -------- ------ -------- -------- --------
  *FADS1*      rs174545          ---     ---      ---       ---      ---      ---      G       32.9     G      31.1     ---      ---
               rs174546          ---     ---      ---       ---      ---      ---      T       32.9     T      31       T        31
               rs174548          G       27       G         22       C        30.1     ---     ---      ---    ---      ---      ---
               rs174556          G       27       G         24       A        29.6     T       30.7     T      28.5     ---      ---
               rs174561          A       27       A         24       G        29.6     C       30.7     C      28.5     ---      ---
  Intergenic   rs3834458         T       22       NA        NA       del      33.0     del     33.1     del    31       ---      ---
               rs968567          T       NA       NA        NA       T        16.9     ---     ---      ---    ---      T        16
  *FADS2*      rs174570          C       23       C         27       T        12.6     ---     ---      ---    ---      T        11
               rs174574          C       22       C         20       A        34.0     ---     ---      ---    ---      ---      ---
               rs2727271         T       25       T         40       T        11.6     ---     ---      ---    ---      ---      ---
               rs174576          C       22       C         21       A        34.0     ---     ---      ---    ---      ---      ---
               rs174578          T       22       T         21       A        34.0     ---     ---      ---    ---      ---      ---
               rs174579          T       28       T         38       T        21.4     ---     ---      ---    ---      ---      ---
               rs174602          T       41       T         37       G        20.4     ---     ---      ---    ---      C        22
               rs498793          T       15       T         35       T        39.9     ---     ---      ---    ---      C        40
               rs526126          G       22       NA        NA       G        18.1     ---     ---      ---    ---      G        20
               rs174575          G       30       G         40       NA       NA       ---     ---      ---    ---      ---      ---
  Intergenic   rs174448          C       48       T         29       C        35.9     ---     ---      ---    ---      ---      ---
               rs174449          T       47       T         28       C        35.1     ---     ---      ---    ---      ---      ---
  *FADS3*      rs174455          T       45       T         22       C        34.8     ---     ---      ---    ---      ---      ---

^1^ALSPAC, Avon Longitudinal Study of Parents and Children; dbSNP, database single-nucleotide polymorphism; del., deleted; *FADS*, fatty acid desaturase; HELENA, Healthy Lifestyle in Europe by Nutrition in Adolescence; ISADI, Indonesian Study of Atopic Dermatitis of Indonesian Infants; KOALA, "Kind, Ouders en gezondheid: Aandacht voor Leefstijl en Aanleg" Birth Cohort Study; LISA, Influences of Lifestyle-related Factors on the Immune System and the Development of Allergies in Childhood Study; MAF, minor allele frequency; POSGRAD, Prenatal Omega-3 Supplementation on Child Growth and Development.

[**Tables 4**](#tbl4){ref-type="table"} and [**5**](#tbl5){ref-type="table"} list the regression coefficients (β coefficients), related *P* values, and explained variance (*R*^2^) of the regression of each fatty acid level, from n--6 and n--3 (% wt/wt), respectively, for each of the 14 analyzed SNPs of the *FADS* gene clusters. The composition of the n--6 fatty acids and ratios of DGLA to LA, ARA to DGLA, and ARA to LA were significantly associated with almost all SNPs of the *FADS1* and most of *FADS2* gene clusters, even after Bonferroni correction of *P* values for multiple testing. However, genetic variants of rs498793, rs526126, and rs174575 of the *FADS2* gene; rs174448 and rs174449 of the intergenic *FADS2* and *FADS3* gene; and rs174455 of the *FADS3* gene, showed no (or only rarely) statistically significant relations with any of the n--6 fatty acids, after correction for multiple testing.

###### 

Regression of n--6 levels (wt% of cord plasma glycerophospholipids) on each of 14 SNPs of the *FADS1--3* regions^[1](#tb4fn1){ref-type="table-fn"}^

                                           Fatty acid                                                                                                                                                                                          
  ------------ ----------- --------------- ----------------------- ---------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------- ---------------------- ---------------------- ----------------------
  *FADS1*      rs174548    β coefficient   −0.562                  0.062            −0.046                 −0.835                 1.186                  0.055                  0.080            −0.053                 0.233                  0.144
                           *P* value       6.97 × 10^--10^\*\*\*   5.28 × 10^-04^   1.89 × 10^-06\*\*\*^   4.51 × 10-42\*\*\*     3.71 × 10^-21\*\*\*^   8.72 × 10^-05\*\*\*^   2.42 ×10^-03^    6.44 × 10^-08\*\*\*^   1.58 × 10^-45\*\*\*^   3.97 × 10^-22\*\*\*^
                           *R* ^2^, %      9.2                     2.8              5.5                    37.9                   20.4                   3.7                    2.1              7.1                    40.4                   21.3
  Intergenic   rs3834458   β coefficient   −0.659                  0.059            −0.053                 −0.877                 1.298                  0.060                  0.101            −0.050                 0.249                  0.163
                           *P* value       7.39 × 10^-12\*\*\*^    1.66 ×10^-03^    2.1 × 10-^07\*\*\*^    4.72 × 10^-41\*\*\*^   1.33 × 10^-22\*\*\*^   5.38 × 10^-05\*\*\*^   3.21 × 10^-04^   1.71 × 10^-06\*\*\*^   2.49 × 10^-46\*\*\*^   1.97 × 10^-25\*\*\*^
                           *R* ^2^, %      11.2                    2.3              6.5                    37.2                   21.8                   3.9                    3.1              5.5                    41.0                   24.4
  *FADS2*      rs174570    β coefficient   −0.650                  0.059            −0.053                 −0.795                 1.249                  0.051                  0.084            −0.042                 0.230                  0.158
                           *P* value       5.8 × 10^-12^\*\*\*     1.35 ×10^-03^    1.06 × 10^-07\*\*\*^   6.23 × 10^-34\*\*\*^   1.2 × 10^-21\*\*\*^    5.05 × 10^-04^         2.37 × 10^-03^   6.06 × 10^-05\*\*\*^   5.29 × 10^-40\*\*\*^   5.7 × 10^-25\*\*\*^
                           *R* ^2^, %      11.3                    2.4              6.8                    31.6                   20.9                   2.8                    2.1              3.8                    36.4                   23.9
               rs174574    β coefficient   −0.674                  0.058            −0.052                 −0.870                 1.297                  0.056                  0.099            −0.048                 0.247                  0.165
                           *P* value       3.44 × 10^-12^\*\*\*    2.27 ×10^-03^    3.9 × 10^-07\*\*\*^    2.06 × 10^-39\*\*\*^   3.45 × 10^-22\*\*\*^   1.74 × 10^-04\*\*\*^   4.79 × 10^-04^   5.39 × 10^-06\*\*\*^   1.26 × 10^-44\*^       1.33 × 10^-25\*\*\*^
                           *R* ^2^, %      11.6                    2.1              6.2                    35.9                   21.4                   3.3                    2.9              5.0                    39.8                   24.5
               rs2727271   β coefficient   0.355                   −0.022           0.021                  0.403                  −0.760                 −0.016                 −0.045           0.018                  −0.124                 −0.093
                           *P* value       1.34 × 10^-05\*\*\*^    1.6 ×10^-01^     1.38 × 10^-02^         9.54 × 10^-12\*\*\*^   2.79 × 10^-11\*\*\*^   1.96 × 10^-01^         5.37 × 10^-02^   4.52 × 10^-02^         3.79 × 10^-15\*\*\*^   5.9 × 10^-12\*\*\*^
                           *R* ^2^, %      4.6                     0.3              1.3                    11.1                   10.6                   0.2                    0.7              0.8                    14.6                   11.3
               rs174576    β coefficient   −0.669                  0.056            −0.051                 −0.851                 1.251                  0.056                  0.101            −0.046                 0.241                  0.161
                           *P* value       3.48 × 10^-12^\*\*\*    2.86 ×10^-03^    6.32 ×10^-07\*\*\*^    4.3 × 10-38\*\*\*      7.09 × 10^-21\*\*\*^   1.83 × 10^-04\*\*\*^   3.15 × 10^-04^   1.11 × 10^-05\*\*\*^   1.47 × 10^-42\*\*\*^   7.55 × 10^-25\*\*\*^
                           *R* ^2^, %      11.6                    2.0              6.0                    34.9                   20.2                   3.3                    3.1              4.6                    38.3                   23.8
               rs174579    β coefficient   0.130                   −0.020           0.018                  0.233                  −0.140                 −0.026                 −0.028           0.018                  −0.053                 −0.023
                           *P* value       1.63 × 10^-01^          2.66 × 10^-01^   5.54 × 10^-02^         6.2 × 10^-04^          2.92 × 10^-01^         6.02 × 10^-02^         2.97 × 10^-01^   6.54× 10^-02^          3.82× 10^-03^          1.42 × 10^-01^
                           *R* ^2^, %      0.2%                    0.1%             0.7%                   2.7%                   0.0%                   0.7%                   0.0%             0.6%                   1.9%                   0.3%
               rs174602    β coefficient   −0.220                  0.021            −0.016                 −0.375                 0.527                  0.027                  0.047            −0.028                 0.105                  0.059
                           *P* value       7.99 × 10^-03^          1.85× 10^-01^    6.04 × 10^-02^         3.71 × 10^-10\*\*\*^   6.56 × 10^-06\*\*\*^   2.96 × 10^-02^         4.73 × 10^-02^   1.64 × 10^-03^         8.12 × 10^-11\*\*\*^   2.26 × 10^-05\*\*\*^
                           *R* ^2^, %      1.6%                    0.2%             0.7%                   9.4%                   4.9%                   1.0%                   0.8%             2.3%                   10.1%                  4.3%
               rs498793    β coefficient   0.111                   −0.004           0.028                  0.174                  −0.311                 −0.012                 −0.029           0.013                  −0.052                 −0.031
                           *P* value       3.6× 10^-01^            8.67 × 10^-01^   2.35 × 10^-02^         4.99 × 10^-02^         6.96 X 10^-02^         5.14 × 10^-01^         3.97 × 10^-01^   3.07 × 10^-01^         3.15 × 10^-02^         1.27 × 10^-01^
                           *R* ^2^, %      0.0                     −0.3             1.1                    0.7                    0.6                    −0.1                   −0.1             0.0                    0.9                    0.3
               rs526126    β coefficient   0.056                   −0.001           0.008                  0.135                  −0.424                 0.009                  0.022            0.012                  −0.053                 −0.033
                           *P* value       5.55 × 10^-01^          9.67 × 10^-01^   4\. × 10^-01^          5.53 × 10^-02^         1.68 × 10^-03^         5.23 × 10^-01^         4.21 × 10^-01^   2.45 × 10^-01^         5.02 × 10^-03^         3.8 × 10^-02^
                           *R* ^2^, %      −0.2                    −0.3             −0.1                   0.7                    2.3                    −0.2                   −0.1             0.1                    1.8                    0.9
               rs174575    β coefficient   0.138                   −0.019           0.015                  0.264                  −0.136                 −0.031                 −0.040           0.021                  −0.059                 −0.024
                           *P* value       1.3× 10^-01^            2.7 × 10^-01^    1.21 × 10^-01^         7.5 × 10^-05\*\*\*^    2.96 x 10^-01^         2.42 × 10^-02^         1.26 x 10^-01^   2.98 × 10^-02^         1.21 × 10^-03^         1.23 × 10^-01^
                           *R* ^2^, %      0.3                     0.1              0.4                    3.7                    0.0                    1.1                    0.3              1.0                    2.4                    0.4
  Intergenic   rs174448    β coefficient   0.129                   −0.009           0.009                  0.133                  −0.103                 −0.023                 −0.065           0.004                  −0.032                 −0.023
                           *P* value       1.18 × 10^-01^          5.79 × 10^-01^   2.95 × 10^-01^         2.94 × 10^-02^         3.8 × 10^-01^          6.93 × 10^-02^         5.73 × 10^-03^   6.44 × 10^-01^         5.02 × 10^-02^         1\. × 10^-01^
                           *R* ^2^, %      0.4                     −0.2             0.0                    1.0                    −0.1                   0.6                    1.7              −0.2                   0.7                    0.4
  Intergenic   rs174449    β coefficient   −0.158                  0.015            −0.015                 −0.206                 0.183                  0.021                  0.065            −0.009                 0.051                  0.032
                           *P* value       4.99 × 10^-02^          3.44 × 10^-01^   7.25 × 10^-02^         4.85 × 10^-04^         1.11 × 10^-01^         8.95 × 10^-02^         4.72 × 10^-03^   2.85 × 10^-01^         1.5 × 10^-03^          1.74 × 10^-02^
                           *R* ^2^, %      0.7                     0.0              0.6                    2.9                    0.4                    0.5                    1.8              0.0                    2.3                    1.2
  *FADS3*      rs174455    β coefficient   −0.173                  0.007            −0.007                 −0.162                 0.130                  0.018                  0.066            −0.004                 0.039                  0.030
                           *P* value       3.5 × 10^-02^           6.45 × 10^-01^   4.29 × 10^-01^         7.36 × 10^-03^         2.68 × 10^-01^         1.51 × 10^-01^         4.5 × 10^-03^    6.66 × 10^-01^         1.75 × 10^-02^         2.97 × 10^-02^
                           *R* ^2^, %      0.9                     −0.2             −0.1                   1.6                    0.1                    0.3                    1.8              −0.2                   1.2                    1.0

^1^Outcome is respective fatty acid wt% of cord plasma glycerophospholipids; ln indicates whether the outcome was log transformed to account for severe right skewness of the fatty acid distribution, or entered into the regression equation on the original scale. The β coefficient is the estimated regression coefficient from unadjusted linear regression of each fatty acid on each genetic variant of the *FADS* gene regions. The *P* values are uncorrected for multiple testing, with \*\*\* indicating significance after Bonferroni correction for multiple testing (critical *P* value is 1.84 × 10^--4^).

###### 

Regression of n--3 levels (wt% of cord plasma glycerophospholipids) on each of 14 SNPs of *FADS1--3* regions^[1](#tb5fn1){ref-type="table-fn"}^

                                           Fatty acid                                                                           
  ------------ ----------- --------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  *FADS1*      rs174548    β coefficient   −0.076           0.015            0.012            0.013            0.0260           0.088
                           *P* value       1.22 × 10^--2^   2.21 × 10^−01^   7.22 × 10^−01^   6.75 × 10^−01^   4.34 × 10^−03^   3.31 × 10^−02^
                           *R* ^2^, %      1.4              0.1              −0.2             −0.2             1.8              0.9
  Intergenic   rs3834458   β coefficient   −0.096           0.014            −0.012           −0.003           0.318            0.083
                           *P* value       2.83 × 10^−03^   3.11 × 10^−01^   7.31 × 10^−01^   9.36 × 10^−01^   9.65 × 10^−04^   5.79 × 10^−02^
                           *R* ^2^, %      2.0              0.0              −0.2             −0.3             2.5              0.7
  *FADS2*      rs174570    β coefficient   −0.091           0.012            −0.001           −0.004           0.302            0.090
                           *P* value       3.95 × 10^−03^   3.43 × 10^−01^   9.8 × 10^−01^    8.93 × 10^−01^   1.45 × 10^−03^   3.69 × 10^−02^
                           *R* ^2^, %      1.9              0.0              −0.3             −0.3             2.3              0.9
               rs174574    β coefficient   −0.100           0.012            −0.007           −0.010           0.299            0.093
                           *P* value       1.89 × 10^−03^   3.89 × 10^−01^   8.38 × 10^−01^   7.63 × 10^−01^   2.15 × 10^−03^   3.55 × 10^−02^
                           *R* ^2^, %      2.2              −0.1%            −0.2             −0.2             2.2              0.9
               rs2727271   β coefficient   0.070            −0.016           0.000            0.005            −0.178           −0.071
                           *P* value       8.34 × 10^−03^   1.55 × 10^−01^   9.97 × 10^−01^   8.43 × 10^−01^   2.73 × 10^−02^   5.32 × 10^−02^
                           *R* ^2^, %      1.5              0.3              −0.3             −0.2             1.0              0.7
               rs174576    β coefficient   −0.101           0.010            −0.009           −0.008           0.296            0.093
                           *P* value       1.53 × 10^−03^   4.43 × 10^−01^   8.14 × 10^−01^   7.98 × 10^−01^   2.23 × 10^−03^   3.4 × 10^−02^
                           *R* ^2^, %      2.3              −0.1             −0.2             −0.2             2.1              0.9
               rs174579    β coefficient   −0.001           0.11             0.004            0.001            −0.033           0.005
                           *P* value       9.76 × 10^−01^   3.66 × 10^−01^   9.09 × 10^−01^   9.86 × 10^−01^   7.2 × 10^−01^    9.08 × 10^−01^
                           *R* ^2^, %      −0.3             0.0              −0.3             −0.3             −0.2             −0.3
               rs174602    β coefficient   −0.046           −0.012           −0.012           −0.028           0.076            0.034
                           *P* value       8.7 × 10^−02^    2.76 × 10^−01^   6.85 × 10^−01^   2.9 × 10^−01^    3.53 × 10^−01^   3.58 × 10^−01^
                           *R* ^2^, %      0.5              0.0              −0.2             0.0              0.0              0.0
               rs498793    β coefficient   0.034            0.009            0.036            0.018            0.043            0.002
                           *P* value       3.92 × 10^−01^   5.65 × 10^−01^   4.19 × 10^−01^   6.45 × 10^−01^   7.17 × 10^−01^   9.69 × 10^−01^
                           *R* ^2^, %      −0.1             −0.2             −0.1             −0.2             −0.2             −0.3
               rs526126    β coefficient   0.071            0.020            −0.049           −0.005           −0.137           −0.120
                           *P* value       2.22 × 10^−02^   1.15 × 10^−01^   1.59 × 10^−01^   8.84 × 10^−01^   1.43 × 10^−01^   4.41 × 10^−03^
                           *R* ^2^, %      1.1              0.4              0.3              −0.3             0.3              1.8
               rs174575    β coefficient   −0.001           0.010            0.015            0.008            −0.016           0.015
                           *P* value       9.85 × 10^−01^   4.25 × 10^−01^   6.55 × 10^−01^   7.87 × 10^−01^   8.61 × 10^−01^   7.02 × 10^−01^
                           *R* ^2^, %      −0.3             −0.1             −0.2             −0.2             −0.3             −0.2
  Intergenic   rs174448    β coefficient   0.129            −0.009           0.009            0.133            −0.103           −0.023
                           *P* value       1.18 × 10^−01^   5.79 × 10^−01^   2.95 × 10^−01^   2.94 × 10^−02^   3.8 × 10^−01^    6.93 × 10^−02^
                           *R* ^2^, %      0.4              −0.2             0.0              1.0              −0.1             0.6
  Intergenic   rs174449    β coefficient   −0.020           0.007            −0.044           −0.028           0.006            −0.023
                           *P* value       4.38 × 10^−01^   5.02 × 10^−01^   1.37 × 10^−01^   2.91 × 10^−01^   9.38 × 10^−01^   5.12 × 10^−01^
                           *R* ^2^, %      −0.1             −0.1             0.3              0.0              −0.3             −0.1
  *FADS3*      rs174455    β coefficient   −0.024           −0.002           −0.053           −0.036           −0.007           −0.029
                           *P* value       3.77 × 10^−01^   8.34 × 10^−01^   7.75 × 10^−02^   1.71 × 10^−01^   9.34 × 10^−01^   4.2 × 10^−01^
                           *R* ^2^, %      −0.1             −0.2             0.5              0.2              −0.3             −0.1

^1^Outcome is respective fatty acid (wt% of cord plasma glycerophospholipids); ln indicates whether the outcome was log transformed to account for severe right skewness of the fatty acid distribution, or entered into the regression equation on the original scale. β Coefficient is the estimated regression coefficient from unadjusted linear regression of each fatty acid on each genetic variant of the *FADS* gene regions. The *P* values are uncorrected for multiple testing (critical *P* value is 1.84 × 10^--4^). *FADS*, fatty acid desaturase; SNP, single-nucleotide polymorphism.

The variance (*R*^2^) of fatty acid levels explained by SNPs was highest for DGLA, with 37.9% for genetic variants in the *FADS1*gene, 37.2% for rs3834458 (intergenic *FADS1/2*), and 35.9% for rs174574 in the *FADS2* gene. The next highest *R*^2^ was 21.8% for regression of ARA in rs3834458 (intergenic *FADS1/2*), followed by ∼20% for *FADS1* and some *FADS2* genetic variants.

The explained variance (*R*^2^) for the ARA:DGLA ratio was mainly determined by genetic variants of *FADS1* or intergenic *FADS1/2* and some *FADS2* genetic variants, accounting for 41.0% (rs3834458) of variation of the ratio. This finding supports the conclusion that the *FADS1* gene product is involved in D5-desaturation from DGLA to ARA. In addition, the *FADS2* gene product D6D is involved.

The high explained variance (*R*^2^) for the ARA:LA ratio for some *FADS2*-related SNPs of 25.5% (rs174574), and the *FADS1/2* intergenic SNP rs3834458 with 24.4%, provides further evidence that the *FADS2* gene product is involved in D6-desaturation from LA to ARA. In contrast, only small amounts of variance ranging from \<1% to 2.5% of n--3 fatty acids were explained by *FADS* SNPs in this Indonesian infant population. The highest *R*^2^ of 2.5% was found for the *FADS1/2* intergenic SNP rs3834458 with regards to DHA level, followed by *R*^2^ \>2.0% for some SNPs of the *FADS2* gene (rs174570 rs174574, rs174576, and rs174578). This finding provides further support that the *FADS2* gene product is involved in D6-desaturation. Interestingly, the explained variance for the EPA:ALA ratio was \<1% for all SNPs, except for rs526126 (*FADS2*), with an *R*^2^ of 1.8%.

DISCUSSION {#sec5}
==========

Our study demonstrated a significant association of cord blood composition of precursor PUFAs and LC-PUFAs with common variants in the *FADS* gene clusters. In this population-based study, we found a higher content of ARA (15.57% ± 1.65%) and DHA (5.12% ± 1.14%) than other PUFAs in umbilical artery plasma glycerophospholipids. This finding is in agreement with those of the LISA Study ([@bib24]), and reflects the active and preferential maternal-fetal transfer of LC-PUFAs across the human placenta ([@bib25], [@bib26]).

The extent to which the fetus can produce LC-PUFAs from precursors, i.e., from n--6 LA and n--3 ALA, is unknown. LC-PUFA formation is facilitated by both elongases encoded by *ELOVL* genes and by desaturases encoded by *FADS* genes ([@bib27]). In our study, we found a close association between *FADS* SNPs and indicators of the activity of *FADS1*- and *FADS2*-encoded enzymes, i.e., blood levels of n--6 LC-PUFAs. As much as 20.4% of the ARA level variation was determined by the rs174548 SNP. Effects of similar size were also found for other SNPs. In contrast, Lattka et al. ([@bib20]) showed that variations of *FADS* genes had a relativity low impact on LC-PUFA composition in cord venous plasma fatty acid, with a coefficient of variation of 2.99% determined by *FADS* SNPs. Umbilical artery samples may better reflect the effects of *FADS* SNP variation because the umbilical artery transports blood from the fetus back to the placenta.

We assessed 18 SNPs from the *FADS1*--*3* gene clusters, but only 14 SNPs were included in further analyses, in order to avoid informational repetition. HWE in this study population had a value of \>5%, which indicated that the population is in a constant state and not influenced by mutations, natural selection, nonrandom mating, genetic drift, or gene flow.

Indeed, we noted different *FADS1* and *FADS2* SNPs distributions in our Indonesian population compared with European populations. We then explored minor alleles in different populations. The major alleles of European populations ([@bib7], [@bib8], [@bib20], [@bib23]) were the minor alleles of the ISADI population. Comparing the minor SNP differences between the British ALSPAC Study ([@bib20]) and the ISADI Study, we found a 70% difference for all SNPs, except for rs968567, rs2727271, rs174579, rs498793, and rs526126. On the other hand, 14 out of 15 minor alleles examined were the same among participants of the Indonesian ISADI study and the Mexican POSGRAD Study ([@bib22]) (namely, rs174548, rs174556, rs174561, rs174570, rs174574, rs2727271, rs174576, rs174578, rs174579, rs174602, rs498793, rs174575, rs174449, and rs174455).

In addition, we found that minor alleles in different populations appeared to have different functional effects. In our study, the minor alleles in Indonesian infants were associated with lower levels of substrates (LA and ALA) and higher levels of products (DGLA and ARA) and ratios of DGLA/LA, ARA/DGLA, and ARA/LA, indicating higher desaturase activity. In contrast, the minor alleles of European populations were associated with higher substrate and lower LC-PUFA levels, indicating lower desaturase activity ([@bib9], [@bib13], [@bib20], [@bib23]). The difference in the activity of *FADS* genes of different populations might be the source of heterogeneity in the meta-analysis, as it was not accounted for in almost all of the past trials ([@bib3]).

Our findings begged the question as to the reason for great variations in the *FADS* gene clusters between populations. Our observations support the theories of natural selection ([@bib28]) and human migration effects ([@bib31]). Indonesia has the world\'s second-longest coastline. The coastline of the country is ∼54,720 km long, hence, fish and other marine mammals are common food sources. This result was similar to the study of Fumagalli et al. ([@bib29]) in an Inuit population. They found higher amounts of substrate n--3 fatty acids and a decrease in the amounts of EPA and DPA, with no significant effect on DHA. The similar changes could, therefore, be an effect of selection driven by environmental conditions, i.e., a habitual diet rich in LC-PUFAs that did not provide an advantage to individuals with a genetically rapid LC-PUFA synthesis ([@bib29]). Agricultural diets, on the other hand, would have led to a higher consumption of grains and other plant-derived foods. Alleles that increase the rate of conversion of short-chain PUFAs to LC-PUFAs would, therefore, have been favored ([@bib30]).

The 93% resemblance between Indonesian and Mexican *FADS* SNPs, and the 70% difference in the ALSPAC Study population, might support the theory of human migration known as "out of Africa" that divides ancestor migration from Africa, either heading west to Europe or heading east to Asia and onwards to Latin America ([@bib31]). Karafet et al. ([@bib32]) found that the Y chromosome of the western Indonesian population was related to haplogroups that may have entered Indonesia during the Paleolithic era from mainland Asia, whereas a study by Moreno-Estrada et al. ([@bib33]) stated that some Mexican ancestors originated from Eastern Asia.

In addition to the the association of *FADS1* and *FADS2* SNPs with LC-PUFA composition, we also assessed for a possible association between rs174455 from the *FADS3* gene and LC-PUFA composition. No significant association was revealed, but there was a trend in the same direction as *FADS1* and *FADS2*. This finding was similar to a study by Koletzko et al. ([@bib14]), who found a weak association between rs174455 and changes in substrates and products. Two special SNPs, rs2727271 and rs498793, showed effects in the opposite direction compared to other SNPs; they decreased products, but increased substrates. Findings for these 2 SNPs were also reported by Lattka et al. ([@bib20]): with only 1 minor allele from rs2727271, there was a 0.76% decrease in ARA level. In addition, the 1 minor allele from rs498793 led to a 0.31% decrease in ARA level.

We found no significant associations between *FADS 1--3* SNPs and n--3 LC-PUFA composition. It appears that maternal dietary EPA and DHA have a greater effect on the cord blood levels of LC-PUFAs than endogenous synthesis.

Sufficient availability of LC-PUFAs is considered essential for early development. In this study, polymorphisms in the *FADS* gene cluster were shown to modify the fatty acid composition of glycerophospholipid plasma of umbilical arterial blood. We can conclude that polymorphisms in fetal *FADS* genes are associated with fetal n--6 LC-PUFA synthesis, in addition to effects of placental transfer of preformed LC-PUFAs. When comparing SNPs of different populations, the similarity of the *FADS1--3* SNP distribution patterns in this Indonesian and a previously studied Mexican population ([@bib22]) are noteworthy, as both differed from European populations. Both the Indonesian and the Mexican populations showed the minor alleles to be associated with high levels of LC-PUFA synthesis, whereas the major genotypes were associated with low levels of LC-PUFA synthesis. Therefore, the supply of preformed LC-PUFA may be particularly important in these populations to achieve similar plasma and tissue concentrations, as well as related biological effects.

As the major alleles of these populations differ and each SNP differs in outcome, direct extrapolation from observational and intervention studies in European populations to Indonesian populations appears questionable, due to their genetically determined differences in PUFA metabolism. Hence, intervention studies in infant populations in Indonesia or other populations with similar genotype distributions seem necessary.
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